Sensus Healthcare, Inc. (NASDAQ:SRTS) is a prominent player in the medical instruments industry, renowned for its cutting-edge healthcare solutions. On November 6, 2025, SRTS disclosed its earnings, revealing an EPS of -$0.06, which was significantly better than the anticipated -$0.11. This performance also exceeded the Zacks Consensus Estimate of a $0.12 loss, marking a positive surprise of 50%.
The company's revenue for the quarter stood at $6.9 million, outperforming the estimated $6.3 million. This figure was slightly higher than the $6.88 million reported for the quarter ending September 2025, surpassing the Zacks Consensus Estimate by 48.36%. However, it fell short of the $8.84 million reported in the same quarter the previous year. Despite this, Sensus Healthcare has outpaced consensus revenue estimates in three of the last four quarters.
Sensus Healthcare's financial metrics present a nuanced view. The company has a negative price-to-earnings (P/E) ratio of approximately -67.74, indicating current losses. However, the price-to-sales ratio of about 1.54 suggests that investors are paying $1.54 for every dollar of sales, which is considered relatively reasonable. The enterprise value to sales ratio of approximately 0.97 may signal a low valuation relative to sales.
The company's enterprise value to operating cash flow ratio stands at around 10.18, reflecting its valuation in relation to cash flow from operations. Despite a negative earnings yield of approximately -1.48%, Sensus Healthcare maintains a strong financial position with a debt-to-equity ratio of about 0.011, indicating minimal debt. Additionally, the company boasts a robust current ratio of approximately 8.14, highlighting its ability to cover short-term liabilities with short-term assets.
